TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07138014: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of FHND1002 Granules in Patients With Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 180 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07138014 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07138014 Rescue Dossier →